Receiving a diagnosis of multiple myeloma can be frightening because it is a cancer that affects the bone marrow, where blood cells are made.
Although there is still no cure for most people, treatment has advanced rapidly over the past decade. Many patients now live much longer than they once did thanks to combinations of powerful medicines.
These improvements have created a new challenge for doctors.
The rules used to identify patients with the highest risk of poor outcomes were developed before today’s treatments became common. As treatments improve, older definitions may no longer reflect what actually happens to patients.
To address this problem, scientists from the University of Alabama at Birmingham worked with the CoMMiT consortium to study people receiving the latest standard treatments. Their research was published in the journal Cancer. The goal was to find a better way to recognize patients who still face a very difficult outlook despite receiving the best available care.
The study included 310 adults with newly diagnosed multiple myeloma.
Everyone received a modern four-drug treatment plan that combined several different types of anti-cancer medicines, followed by an autologous stem cell transplant whenever appropriate. Researchers tracked the participants for a median of three and a half years.
Years ago, doctors considered a patient to have functional high-risk disease if the cancer came back within 18 months after treatment began. That definition was useful when treatment options were more limited. However, because current therapies keep many patients well for longer, researchers wondered if the timing should be updated.
The results showed that patients whose cancer returned within 36 months of starting treatment were much more likely to survive for less than two years after the disease progressed. This new 36-month definition was better at identifying people with the poorest prognosis than the older 18-month rule.
The researchers called this updated group FHR36. Around one in six patients belonged to this category. Identifying them earlier could help doctors offer more aggressive or experimental treatments before the disease becomes even harder to control.
One promising option is T-cell redirecting therapy. Instead of attacking cancer directly, these medicines guide the body’s own immune cells toward myeloma cells, helping the immune system destroy them. The study suggested these therapies may slow disease progression and could be especially valuable for patients in the FHR36 group.
According to senior researcher Dr. Luciano J. Costa, the new definition should also improve the design of future clinical trials. If researchers focus on patients with the greatest need, they may discover new treatments faster and learn which therapies work best for this high-risk group.
Overall, this study shows that advances in treatment can change how doctors should measure risk. Rather than proving a new medicine works, the research updates an important clinical definition that may influence future care.
The findings are strong because they reflect patients treated with modern therapy, but additional studies in larger groups and different hospitals will help confirm the results and strengthen future treatment guidelines.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Source: University of Alabama at Birmingham.
